Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
viracept
roche registration ltd. - nelfinavir - hiv infektioner - antivirale midler til systemisk anvendelse - viracept er indiceret ved antiretroviral kombinationsbehandling af hiv-1-inficerede mennesker, unge og børn på tre år og ældre med humane immunsvigt. i protease-hæmmer (pi)-erfarne patienter, valg af nelfinavir bør være baseret på individuelle viral resistens test og behandling, historie.
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
cisatracurium "fresenius kabi" 2 mg/ml injektions-/infusionsvæske, opløsning
fresenius kabi ab - cisatracuriumbesilat - injektions-/infusionsvæske, opløsning - 2 mg/ml
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
palladon 16 mg depotkapsler, hårde
mundipharma a/s - hydromorphonhydrochlorid - depotkapsler, hårde - 16 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
palladon 24 mg depotkapsler, hårde
mundipharma a/s - hydromorphonhydrochlorid - depotkapsler, hårde - 24 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
palladon 4 mg depotkapsler, hårde
mundipharma a/s - hydromorphonhydrochlorid - depotkapsler, hårde - 4 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
palladon 8 mg depotkapsler, hårde
mundipharma a/s - hydromorphonhydrochlorid - depotkapsler, hårde - 8 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
palladon 20 mg/ml injektions-/infusionsvæske, opløsning
mundipharma a/s - hydromorphonhydrochlorid - injektions-/infusionsvæske, opløsning - 20 mg/ml
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
palladon 50 mg/ml injektions-/infusionsvæske, opløsning
mundipharma a/s - hydromorphonhydrochlorid - injektions-/infusionsvæske, opløsning - 50 mg/ml
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
palladon 2,6 mg kapsler, hårde
mundipharma a/s - hydromorphonhydrochlorid - kapsler, hårde - 2,6 mg
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
blincyto
amgen europe b.v. - blinatumomab - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.